OncoNano's product candidates and interventions are designed to help patients across the continuum of cancer care and include solid tumor therapeutics, a platform of immuno-oncology therapeutics that activate and guide the body’s immune system to target cancer, and agents for real-time image guided surgery.

ONM-501, OncoNano’s first therapeutic program is a next generation dual-activating STING (STimulator of INterferon Genes) agonist in phase I studies as of Q2 2024. ONM-412, the highly potent pro-inflammatory cytokine, interleukin-12 (IL-12).